BMC Proceedings



Poster presentation

Open Access

Differential invasion of *Trypanosoma brucei brucei* and lymphocytes into the brain of C57BL/6

Willias Masocha*¹, Daniel N Amin², Krister Kristensson² and Martin E Rottenberg³

Address: ¹Department of Applied Therapeutics, Faculty of Pharmacy, Kuwait University, Safat 13110, Kuwait, ²Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden and ³Department of Microbiology & Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden

Email: Willias Masocha* - Masocha@hsc.edu.kw

* Corresponding author

from Infectious diseases of the nervous system: pathogenesis and worldwide impact Paris, France. 10-13 September 2008

Published: 23 September 2008

BMC Proceedings 2008, 2(Suppl 1):P38

This abstract is available from: http://www.biomedcentral.com/1753-6561/2/S1/P38

© 2008 Masocha et al; licensee BioMed Central Ltd.

Trypanosoma brucei (T. b.) subspecies invade the brain parenchyma at late stages of human and experimental rodent infections. Here, we compared the outcome of infection with T. b. in MHC-matched (H2b) C57BL/6 (B6) and 129Sv/Ev (Sv-129). While Sv-129 showed higher parasitemia and lower specific IgM (but not IgG) antibody levels than B6 mice, the number of trypanosomes, CD4+ and CD8+T cells in the brain parenchyma was higher in B6 mice. B6 mice lost weight and showed higher cumulative mortality compared to Sv-129 mice. Higher levels of IL-1β, IL-6, IL-10, TNF-α, IFN-γ, ICAM-1 and E-selectin, but low levels of TGF-B mRNA were present in brains of B6 compared to Sv-129-infected mice. Thus, host genetics differentially determine invasion of T. b. brucei into the brain parenchyma, which is paralleled by the severity of inflammation in the brain and course of the disease, but not by parasitemia or antibody titers.

Acknowledgements

This study was supported by a grant from the European Union (NEUROT-RYP; FP6-2004-INCO-DEV-3 032324), the Swedish International Developing Agency (SIDA) and WHO-TDR.